<DOC>
	<DOCNO>NCT00003205</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness bryostatin 1 treat patient stage IV breast cancer .</brief_summary>
	<brief_title>Bryostatin 1 Treating Patients With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical response patient stage IV breast cancer bryostatin 1 . - Determine efficacy regimen patient . - Estimate pharmacokinetic parameter bryostatin 1 give 24 hour infusion . - Determine ability regimen regulate lymphocyte function patient . - Determine effect regimen platelet function protein kinase C activity patient . OUTLINE : Patients receive bryostatin 1 IV 24 hour . Treatment continue weekly absence disease progression unacceptable toxicity . Patients follow every 4-8 week tumor response . PROJECTED ACCRUAL : A total 14-25 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Unequivocal diagnosis metastatic breast cancer Bidimensionally measurable disease No uncontrolled CNS metastases No disease evaluable , include blastic bone disease , malignant ascites , malignant pleural effusion Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : SWOG 02 OR Karnofsky 60100 % Life expectancy : At least 18 week Hematopoietic : Platelet count least 50,000/mm^3 PT PTT within normal limit Neutrophil count least 2,000/mm^3 Hepatic : Bilirubin great 1.2 mg/dL Transaminases great 3 time normal Renal : Creatinine great 1.6 mg/dL OR Creatinine clearance least 70 mL/min Other : No active infection require antibiotic No viral hepatitis allow Seronegative hepatitis B C Not pregnant nursing Fertile patient must use effective contraception 2 month follow study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : 2 prior chemotherapy regimens metastatic disease allow adjuvant therapy advance disease ( may include high dose chemotherapy stem cell support ) At least 4 week since prior chemotherapy At least 6 week since prior nitrosourea mitomycin therapy No concurrent chemotherapy Endocrine therapy : 2 prior hormonal therapy regimens metastatic disease adjuvant therapy advance disease allow At least 2 week since prior hormonal therapy ( least 4 week case disease progression receive hormonal therapy initial response ) No concurrent hormonal therapy except oral contraceptive No concurrent use steroid except management severe life threaten toxic effect arise bryostatin 1 Radiotherapy : At least 2 week since prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : No concurrent use drug know interfere platelet function , aspirin NSAIDs ( include ibuprofen ) No concurrent use anticoagulant At least 2 week since prior use aspirin At least 2 day since prior use NSAIDS Concurrent use acetaminophen control pain allow If acetaminophen inadequate pain control , concurrent use oral narcotic codeine oxycodone allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>